Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
36.7M
-
Shares change
-
+920K
-
Total reported value, excl. options
-
$582M
-
Value change
-
-$99.6M
-
Put/Call ratio
-
1.04
-
Number of buys
-
100
-
Number of sells
-
-69
-
Price
-
$15.83
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q4 2024
212 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2024.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.7M shares
of 40.6M outstanding shares and own 90.47% of the company stock.
Largest 10 shareholders include FMR LLC (5.54M shares), BlackRock, Inc. (2.73M shares), VANGUARD GROUP INC (1.96M shares), BRAIDWELL LP (1.89M shares), Darwin Global Management, Ltd. (1.69M shares), STATE STREET CORP (1.2M shares), Holocene Advisors, LP (1.2M shares), ALKEON CAPITAL MANAGEMENT LLC (1.1M shares), ORBIMED ADVISORS LLC (1.02M shares), and Nantahala Capital Management, LLC (915K shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.